课题基金 / 基金详情

DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE

开发抗酰胺治疗作为治疗辐射暴露急性影响的新型医学对策

批准号：

10932584

负责人：

CHARLES DIMMLER III

金额：

$152.95万

依托单位：

CERAMEDIX HOLDING, LLC

依托单位国家：

美国

项目类别：

财政年份：

2023

资助国家：

美国

项目状态：

已结题

起止时间：

2023-07-01 至 2024-06-30

来源：

https://reporter.nih.gov/project-details/10932584

关键词：

Acute Address Animal Experimentation Apoptosis Biological Blood Vessels Cessation of life Development Endothelium FDA approved Female Injury Ionizing radiation Modeling Mus Organ failure Pegfilgrastim Radiation Radiation Accidents Radiation Injuries Radiation Toxicity Radiation exposure Testing Vascular Endothelium biomarker development gastrointestinal irradiation male medical countermeasure novel radiation effect radiation-induced injury response

项目摘要

项目成果

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文